Incyte Gestion
Gestion contrôle des critères 1/4
Le PDG Incyte est Bill Meury, nommé en Jun2025, a un mandat de 1.08 ans. La rémunération annuelle totale est $ 32.09M, composée du salaire de 2% et des bonus 98%, y compris les actions et options de la société. détient directement 0.002% des actions de la société, d'une valeur de $ 560.97K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.1 ans et 7.6 ans.
Informations clés
Bill Meury
Directeur général
US$32.1m
Rémunération totale
| Pourcentage du salaire du PDG | 2.02% |
| Durée du mandat du directeur général | 1.1yrs |
| Propriété du PDG | 0.002% |
| Durée moyenne d'occupation des postes de direction | 1.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.6yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jul 28
INCY: Future Returns Will Hinge On Replacing Jakafi And Advancing Hematology Pipeline
Analysts have lifted the Incyte fair value estimate from $108.50 to about $114.55, reflecting modestly higher assumptions for revenue growth, profit margins and future P/E, along with a slightly lower discount rate, based on a recent series of upward price target revisions across the Street. Analyst Commentary Recent research on Incyte shows a mix of optimism and caution.Seeking Alpha • Jul 28
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Summary Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-week high of $120.70. In my view, key drivers behind Incyte's recent rally are the promising efficacy of latarcibart in von Willebrand disease, along with strong performance from Opzelura and Zynyz. So, sales of Zynyz rose 20.8% quarter-over-quarter to $50 million in Q2. However, given the sluggish demand for Iclusig and Incyte's forward non-GAAP P/E of 45x, I'm downgrading INCY's rating to Hold. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 14
INCY: Post Jakafi Cliff Will Outweigh Vega Von Willebrand Opportunity
Analysts have lifted the fair value estimate for Incyte stock from $79.38 to $82.16, citing refreshed revenue growth assumptions, updated margins, and a higher future P/E multiple supported by recent price target increases from several research firms following the Vega Therapeutics acquisition and evolving views on the post Jakafi portfolio. Analyst Commentary Recent research on Incyte reflects a mix of optimism around pipeline additions like Vega Therapeutics and continued caution around execution and life after Jakafi.Mise à jour du récit • Jun 30
INCY: Jakafi 2028 Cliff Will Challenge Vega Von Willebrand Acquisition
Incyte's analyst price targets have moved higher, with recent raises into the $94 to $113 range as analysts factor in the Vega Therapeutics acquisition, updated expectations for von Willebrand disease assets, and management's efforts to prepare for Jakafi's eventual loss of exclusivity. Analyst Commentary Recent research coverage on Incyte highlights a mixed backdrop, with several firms lifting price targets into the mid to high US$90s and low US$100s while keeping ratings largely in the middle of the road.Article d’analyse • Jun 17
Incyte (INCY) Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results
Recent interest in Incyte (INCY) stock is closely tied to fresh clinical and regulatory milestones, including pivotal data for zilurgisertib in fibrodysplasia ossificans progressiva and Phase 3 results for tafasitamab plus lenalidomide with R-CHOP. See our latest analysis for Incyte. Incyte stock has cooled slightly in the very short term, with a 1-day share price return of 2.19% and a 7-day share price return of 5.35%. However, the 1-year total shareholder return of 46.11% and 3-year total...
Mise à jour du récit • Jun 16
INCY: Hematology Pipeline And Vega Acquisition Will Cushion Upcoming Patent Cliff
Analysts have nudged the fair value estimate for Incyte up by $5 to $140, citing the Vega Therapeutics acquisition and its Phase 3-ready von Willebrand disease asset as a potential long-term offset to Jakafi loss of exclusivity, while also modestly adjusting assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Recent research on Incyte highlights a split view.Mise à jour du récit • Jun 02
INCY: Jakafi 2028 Cliff Will Expose Uncertain mutCALR Pipeline Transition
Analysts have nudged their fair value estimate for Incyte higher to about $74.53 from $72.33, reflecting updated views on long term revenue pressure after Jakafi’s expected loss of exclusivity, incremental support from early stage assets like INCA033989, and mixed sentiment on longer term growth that has also led to a slightly higher assumed P/E multiple. Analyst Commentary Analyst views on Incyte remain mixed, with the core debate centered on how the company will handle the patent cliff tied to Jakafi and whether early stage assets like INCA033989 can eventually support the current valuation.Article d’analyse • May 10
Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)
Incyte Corporation ( NASDAQ:INCY ) announced strong profits, but the stock was stagnant. We did some digging, and we...Mise à jour du récit • May 03
INCY: Future Returns Will Depend On Managing Patent Cliff And Pipeline Execution
Incyte's updated analyst price target has moved from $100.10 to $108.50, reflecting how analysts are weighing a series of recent target hikes from firms such as Oppenheimer, BofA, RBC, Barclays, Morgan Stanley, Piper Sandler and H.C. Wainwright, against more cautious views from UBS and Jefferies focused on patent and long term growth uncertainties. Analyst Commentary Recent research highlights a clear split in how analysts view Incyte, with several firms lifting price targets or initiating with a positive stance, while others focus on patent risk and long term growth questions.Mise à jour du récit • Apr 18
INCY: Jakafi 2028 Patent Cliff Will Pressure Reliance On Long Dated Pipeline
The analyst price target for Incyte has shifted to reflect a modest fair value increase of about $2, as analysts weigh patent cliff concerns around Jakafi in 2028 against longer term pipeline opportunities and a higher assumed future P/E multiple. Analyst Commentary Recent research has highlighted a split view on Incyte, with some firms lifting price targets while others have taken a more cautious stance.Mise à jour du récit • Apr 04
INCY: Late Stage Pipeline And 2026 Readouts Will Offset Patent Cliff Risk
Analysts have modestly adjusted their price targets on Incyte, with recent cuts of up to $10 alongside several incremental increases. This reflects a balance between concerns around Jakafi's 2028 patent cliff and confidence in longer term revenue drivers that are considered harder to underwrite today.Mise à jour du récit • Mar 21
INCY: Late Stage Pipeline And 2026 Milestones Will Offset Patent Cliff Risk
Analysts' price targets for Incyte have shifted, with one firm cutting its view from $120 to $94 on patent cliff concerns, while others have nudged targets higher into the $90 to $128 range. This reflects a balance between Jakafi loss of exclusivity risk and longer term pipeline potential.Mise à jour du récit • Mar 07
INCY: Late Stage Pipeline Progress And 2026 Readouts Will Reshape Earnings Power
Incyte's updated analyst price target has nudged higher, with several firms lifting their views into a roughly $117 to $128 range as analysts highlight a clearer revenue roadmap, upcoming Phase 3 catalysts, and a more constructive sector backdrop, despite at least one downgrade on near term catalysts. Analyst Commentary Recent Street research around Incyte has tilted constructive, with several bullish analysts revisiting their models and lifting price targets as they get more confidence in the company’s roadmap and execution plans.Mise à jour du récit • Feb 21
INCY: Late Stage Pipeline Execution Will Reshape Earnings Power Beyond Jakafi
The analyst fair value estimate for Incyte has been raised by $6 to $135. This change reflects recent price target increases across several firms as analysts point to a fuller pipeline, higher assumed revenue growth, a higher future P/E multiple, and offsetting adjustments to discount rate and profit margin assumptions.Mise à jour du récit • Feb 06
INCY: Late Stage Pipeline Reliance Will Face Pressure As Near Term Catalysts Remain Scarce
Analysts have lifted their price targets on Incyte by as much as US$27, citing a fuller late stage pipeline, new coverage with bullish views, and updated assumptions around discount rates, revenue growth, profit margins, and forward P/E that support a higher valuation range. Analyst Commentary Recent research on Incyte has tilted more constructive on potential upside, but there are also clear points of caution that investors should keep in mind when thinking about valuation and execution risk.Mise à jour du récit • Jan 23
INCY: Late Stage Pipeline Execution Will Face Scrutiny As Near Term Catalysts Thin
Narrative Update: Incyte (INCY) The updated analyst price target for Incyte moves from $60 to $70, reflecting analysts' incorporation of higher projected profit margins, a lower future P/E, and recent price target raises that highlight a fuller late stage pipeline and upcoming clinical readouts, even as some research points to fewer near term catalysts. Analyst Commentary Recent Street commentary on Incyte mixes higher price targets with tempered expectations around the pace and reliability of execution.Mise à jour du récit • Jan 09
INCY: Pipeline Progress And Policy Tailwinds Will Reshape Earnings Power
Analysts have lifted their fair value estimate for Incyte to $129 from $92, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent Street research, including the higher $90 price target cited by Goldman Sachs. Analyst Commentary Recent Street research has added a more constructive tone around Incyte, with bullish analysts pointing to updated assumptions on risk, growth, and profitability to support higher valuation frameworks.Mise à jour du récit • Dec 25
INCY: Future Returns Will Hinge On Executing High-Expectation Pipeline Under New Leadership
Analysts have nudged their price target on Incyte slightly higher, to $82 from $81. This reflects a modestly improved fair value estimate even as they caution that the recent share rally has largely priced in high expectations for key pipeline assets and new management.Mise à jour du récit • Dec 11
INCY: Future Returns Will Depend On Delivering High-Risk Hematology Pipeline Milestones
Analysts have nudged their fair value estimate for Incyte higher, lifting the implied price target by about $4 per share to roughly $100. They are balancing moderate upward revisions to growth assumptions and valuation multiples against a view that recent gains already reflect high expectations for key pipeline assets and Opzelura expansion.Mise à jour du récit • Nov 27
INCY: Share Momentum Will Slow As R&D Execution Risks Remain Elevated
Incyte's analyst price target has increased modestly to $95.57 from $93.82. Analysts cite continued pipeline momentum, recent regulatory approvals, and new leadership as key drivers supporting higher valuation expectations.Mise à jour du récit • Nov 12
INCY: Share Momentum Will Stall As Execution Risks Come Into Focus
Incyte's analyst price target has increased from $86.86 to $93.82, as analysts cite improving profit margins, strong product pipeline updates, and enhanced growth visibility following recent regulatory and clinical developments. Analyst Commentary Recent analyst research on Incyte reflects a range of perspectives on the company's valuation, growth potential, and commercial execution.Article d’analyse • Oct 31
Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
Incyte Corporation ( NASDAQ:INCY ) defied analyst predictions to release its quarterly results, which were ahead of...Mise à jour du récit • Oct 29
Upcoming Clinical Data And New Management Will Shape Future Performance
Incyte's analyst fair value price target has been raised by nearly $2 to approximately $87, as analysts point to recent clinical updates and pipeline progress strengthening the company's growth outlook. Analyst Commentary Recent Street research on Incyte reflects a mix of optimism regarding the company's growth drivers and caution about valuation and future risks.Mise à jour du récit • Oct 15
Pipeline And Precision Medicine Will Transform Global Immunotherapy Landscape
Incyte's analyst price target has increased slightly from $83.62 to $84.76, as analysts cite ongoing commercial momentum and incremental advances in the company's growth drivers. Analyst Commentary Recent analyst activity reflects a range of perspectives on Incyte’s outlook, with notable adjustments to ratings and price targets based on pipeline progress, commercial momentum, and valuation concerns.Mise à jour du récit • Sep 26
Pipeline And Precision Medicine Will Transform Global Immunotherapy Landscape
Increased analyst confidence in Incyte’s pipeline progress, strong Opzelura execution, and management’s ability to offset Jakafi’s patent expiry has driven the consensus price target up from $81.55 to $83.62. Analyst Commentary Bullish analysts highlight increased visibility and incremental growth from FDA approval of Opzelura for pediatric atopic dermatitis, along with strong commercial execution under new leadership.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$2b |
| Mar 31 2026 | n/a | n/a | US$1b |
| Dec 31 2025 | US$32m | US$647k | US$1b |
Rémunération vs marché: La rémunération totale de Bill ($USD 32.09M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 14.63M ).
Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Bill avec les performances de l'entreprise.
PDG
Bill Meury (58 yo)
1.1yrs
Titularisation
US$32,085,952
Compensation
Mr. William J. Meury, also known as Bill, is Director of Uniquity Bio, Inc. Mr. Meury serves as Director of Anthos Therapeutics, Inc. since April 2024 and was its Chief Executive Officer since April 2024 u...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$32.09m | 0.0021% $ 561.0k | |
| President and Global Head of R&D | less than a year | US$8.84m | 0.024% $ 6.3m | |
| Principal Financial Officer | 4.3yrs | US$990.37k | 0.0043% $ 1.1m | |
| Executive VP | 11.3yrs | US$6.30m | 0.00079% $ 208.1k | |
| Executive Vice President & Head of U.S. Commercial | 1.5yrs | US$10.59m | pas de données | |
| Executive VP & CFO | less than a year | pas de données | pas de données | |
| Executive VP & Head of Global Technical Operations | 10.5yrs | pas de données | 0.0058% $ 1.5m | |
| VP & Head of Investor Relations | no data | pas de données | pas de données | |
| Executive VP | less than a year | pas de données | pas de données | |
| VP of Investor Relations & Corporate Communications | no data | pas de données | pas de données | |
| Executive VP & Chief Human Resources Officer | less than a year | pas de données | pas de données | |
| Group VP | no data | pas de données | pas de données |
1.1yrs
Durée moyenne de l'emploi
58.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de INCY n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$32.09m | 0.0021% $ 561.0k | |
| Independent Director | 11.5yrs | US$536.14k | 0.011% $ 3.0m | |
| Independent Chairman of the Board | 24.7yrs | US$573.14k | 0.14% $ 36.7m | |
| Independent Director | 4.8yrs | US$511.14k | 0.0056% $ 1.5m | |
| Independent Director | 8.7yrs | US$524.64k | 0.0097% $ 2.5m | |
| Independent Director | 6.6yrs | US$539.64k | 0.011% $ 2.8m | |
| Independent Director | 6.3yrs | US$511.14k | 0.0067% $ 1.8m | |
| Independent Director | 11.5yrs | US$538.14k | 0.012% $ 3.2m |
7.6yrs
Durée moyenne de l'emploi
65.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de INCY sont considérés comme expérimentés (ancienneté moyenne 7.6 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/29 05:53 |
| Cours de l'action en fin de journée | 2026/07/29 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Incyte Corporation est couverte par 46 analystes. 18 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Peter Lawson | Barclays |